Bristol Myers Squibb Company (NYSE:BMY) Shares Sold by Foundry Partners LLC

Foundry Partners LLC reduced its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 5.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 385,025 shares of the biopharmaceutical company's stock after selling 21,658 shares during the period. Bristol Myers Squibb accounts for about 1.2% of Foundry Partners LLC's portfolio, making the stock its 15th largest holding. Foundry Partners LLC's holdings in Bristol Myers Squibb were worth $23,483,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also modified their holdings of the stock. Pinney & Scofield Inc. acquired a new stake in Bristol Myers Squibb during the fourth quarter worth approximately $25,000. Park Square Financial Group LLC acquired a new position in Bristol Myers Squibb during the 4th quarter valued at about $26,000. Transce3nd LLC bought a new stake in shares of Bristol Myers Squibb during the 4th quarter worth about $28,000. Global Wealth Strategies & Associates raised its holdings in shares of Bristol Myers Squibb by 137.5% in the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 275 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Bristol Myers Squibb during the first quarter valued at approximately $31,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Insider Transactions at Bristol Myers Squibb

In other news, EVP Samit Hirawat purchased 4,250 shares of the firm's stock in a transaction on Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the purchase, the executive vice president owned 83,513 shares in the company, valued at $3,973,548.54. This trade represents a 5.36% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.09% of the stock is owned by insiders.

Bristol Myers Squibb Trading Down 1.4%

Shares of BMY stock opened at $47.40 on Friday. The business's 50 day moving average is $47.47 and its two-hundred day moving average is $52.94. Bristol Myers Squibb Company has a twelve month low of $41.61 and a twelve month high of $63.33. The company has a market capitalization of $96.46 billion, a P/E ratio of 17.75, a price-to-earnings-growth ratio of 2.47 and a beta of 0.36. The company has a current ratio of 1.28, a quick ratio of 1.17 and a debt-to-equity ratio of 2.65.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The firm had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. During the same period in the previous year, the firm posted ($4.40) earnings per share. Bristol Myers Squibb's revenue was down 5.6% on a year-over-year basis. Equities analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be paid a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.23%. The ex-dividend date is Thursday, July 3rd. Bristol Myers Squibb's payout ratio is currently 92.88%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on BMY. Piper Sandler started coverage on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price objective for the company. William Blair restated a "market perform" rating on shares of Bristol Myers Squibb in a report on Friday, April 25th. Jefferies Financial Group lowered their price objective on shares of Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Morgan Stanley lowered their target price on shares of Bristol Myers Squibb from $36.00 to $34.00 and set an "underweight" rating on the stock in a report on Thursday, July 10th. Finally, Argus raised shares of Bristol Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $57.69.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.